nach oben

Erschienen in:

01.06.2015 | Research Article

Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians

verfasst von: Ruhi Kapahi, Kamlesh Guleria, Vasudha Sambyal, Mridu Manjari, Meena Sudan, Manjit Singh Uppal, Neeti Rajan Singh

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of present study was to evaluate the relationship between vascular endothelial growth factor (VEGF) −2578C/A, −2549I/D, −460T/C and −7C/T and VEGFR1 −710C/T polymorphisms with risk to breast cancer in North Indians. A total of 204 sporadic breast cancer patients and 204 controls were recruited for this case-control study. Significantly increased frequency of II genotype of −2549I/D polymorphism was observed in patients as compared to control individuals (odds ratio (OR) = 2.76, 95 % confidence interval (CI), 1.55–4.92; p = 0.0005). VEGF −2578AA genotype (OR = 2.87; 95 % CI, 1.61–5.10; p = 0.0003) and A allele (OR = 1.65, 95 % CI, 1.25–2.18; p = 0.0004) were found to be associated with increased risk for breast cancer. Individuals carrying CC genotype (OR = 2.23, 95 % CI, 1.25–3.97) and C allele (OR = 1.42, 95 % CI, 1.07–1.87) of VEGF −460T/C polymorphism were at higher risk of breast cancer. There was no significant difference in genotype and allele distribution of VEGF −7C/T and VEGFR1 −710C/T polymorphisms between cases and control individuals (p > 0.05). Linkage disequilibrium analysis showed a strong linkage between VEGF −2549I/D and −2578C/A polymorphisms (Lewontin’s \( \overset{^{\prime }}{D} \) = 0.99; r ² = 0.97), −2549I/D and −460T/C (\( \overset{^{\prime }}{D} \) = 0.94; r ² = 0.84), and −2578C/A and −460T/C polymorphisms (\( \overset{^{\prime }}{D} \) = 0.93; r ² = 0.83). In the present study, we concluded that VEGF −2549I/D, −2578C/A and −460T/C polymorphisms are associated with risk to breast cancer in Punjab, North India.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.CrossRefPubMedPubMedCentral

Schoppmann SF, Horvat R, Birner P. Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies. Oncol Rep. 2002;9(3):455–60.PubMed

Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353–64.CrossRefPubMed

Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.CrossRefPubMed

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.CrossRefPubMed

Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653–60.CrossRefPubMed

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. J Nat Med. 2003;9(6):669–76.CrossRef

Alon T, Hemo I, Itin A, Pe’er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1(10):1024–8.CrossRefPubMed

Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A. 1997;94(16):8761–6.CrossRefPubMedPubMedCentral

10.

Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93(8):1493–5.CrossRefPubMed

11.

Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 1999;60(12):1245–9.CrossRefPubMed

12.

Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 2000;12(8):1232–5.CrossRefPubMed

13.

Akiri G, Nahari D, Finkelstein Y, Le SY, Elroy-Stein O, Levi BZ. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene. 1998;17(2):227–36.CrossRefPubMed

14.

Huez I, Creancier L, Audigier S, Gensac MC, Prats AC, Prats H. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol. 1998;18(11):6178–90.CrossRefPubMedPubMedCentral

15.

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37(6):443–8.CrossRefPubMed

16.

Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002;51(5):1635–9.CrossRefPubMed

17.

Mohammadi M, Ollier WE, Hutchinson IV. A functional association study of VEGF gene promoter polymorphisms with VEGF expression by stimulated pbm cells. Hum Immunol. 2003;64:S125.CrossRef

18.

Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63(4):812–6.PubMed

19.

Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res. 1995;1(9):961–4.PubMed

20.

Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, et al. Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol. 2004;57(5):504–12.CrossRefPubMedPubMedCentral

21.

Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst. 1997;89(2):139–47.CrossRefPubMed

22.

Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer. 2000;89(1):51–62.CrossRefPubMed

23.

Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 2001;61(5):2256–60.PubMed

24.

Kushlinskii NE, Gershtein ES. Role of vascular endothelial growth factor during breast cancer. Bull Exp Biol Med. 2002;133(6):521–8.CrossRefPubMed

25.

Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis. 2003;9:210–6.PubMed

26.

Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005;11(10):3647–53.CrossRefPubMed

27.

Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26(28):4672–8.CrossRefPubMedPubMedCentral

28.

Kidd LR, Brock GN, VanCleave TT, Benford ML, Lavender NA, Kruer TL, et al. Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival. Cancer Causes Control. 2010;21(10):1545–57.CrossRefPubMedPubMedCentral

29.

Kong SY, Park JW, Lee JA, Park JE, Park KW, Hong EK, et al. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology. 2007;46(2):446–55.CrossRefPubMed

30.

Nasr HB, Chahed K, Bouaouina N, Chouchane L. Functional vascular endothelial growth factor -2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression. Clin Chim Acta. 2008;395(1–2):124–9.CrossRefPubMed

31.

Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog. 2009;48(6):563–9.CrossRefPubMed

32.

Kjaer-Frifeldt S, Fredslund R, Lindebjerg J, Hansen TF, Spindler KL, Jakobsen A. Danish Colorectal Cancer Group. Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. Pharmacogenomics. 2012;13(7):763–70.CrossRefPubMed

33.

Jaiswal PK, Tripathi N, Shukla A, Mittal RD. Association of single nucleotide polymorphisms in vascular endothelial growth factor gene with bladder cancer risk. Med Oncol. 2013;30(2):509.CrossRefPubMed

34.

Bruyere F, Hovens CM, Marson MN, D’Arcier BF, Costello AJ, Watier H, et al. VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol. 2010;184(4):1273–8.CrossRefPubMed

35.

Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications. 2003;17(1):1–6.CrossRefPubMed

36.

Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant. 2007;22(3):827–32.CrossRefPubMed

37.

Salvarani C, Boiardi L, Casali B, Olivieri I, Cantini F, Salvi F, et al. Vascular endothelial growth factor gene polymorphisms in Behçet’s disease. J Rheumatol. 2004;31(9):1785–9.PubMed

38.

Kamoun M, Houman MH, Hamzaoui A, Hamzaoui K. Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet’s disease. Tissue Antigens. 2008;72(6):581–7.CrossRefPubMed

39.

Boiardi L, Casali B, Nicoli D, Farnetti E, Chen Q, Macchioni P, et al. Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. J Rheumatol. 2003;30(10):2160–4.PubMed

40.

Breunis WB, Biezeveld MH, Geissler J, Ottenkamp J, Kuipers IM, Lam J, et al. Vascular endothelial growth factor gene haplotypes in Kawasaki disease. Arthritis Rheum. 2006;54(5):1588–94.CrossRefPubMed

41.

George GP, Mittal RD. Association of polymorphic variants of Vascular Endothelial Growth Factor (VEGF) gene in relation to risk and androgen therapy response in Prostate cancer patients of North India. 2011. http://www.ichg2011.org/cgi-bin/showdetail.pl?absno=10216. Accessed 16 May 2014.

42.

Prakash S, Prasad N, Sharma RK, Faridi RM, Agrawal S. Vascular endothelial growth factor gene polymorphisms in North Indian patients with end stage renal disease. Cytokine. 2012;58(2):261–6.CrossRefPubMed

43.

Lee SJ, Lee SY, Jeon HS, Park SH, Jang JS, Lee GY, et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(3):571–5.CrossRefPubMed

44.

Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, et al. Population-based case–control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1148–52.CrossRefPubMed

45.

Cacev T, Loncar B, Seiwerth S, Spaventi S, Kapitanovic S. Vascular endothelial growth factor polymorphisms -1154G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol. 2008;27(10):569–74.CrossRefPubMed

46.

Langsenlehner U, Wolf G, Langsenlehner T, Gerger A, Hofmann G, Clar H, et al. Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian “tumor of breast tissue: incidence, genetics, and environmental risk factors” study. Breast Cancer Res Treat. 2008;109(2):297–304.CrossRefPubMed

47.

Langsenlehner T, Langsenlehner U, Renner W, Krippl P, Mayer R, Wascher TC, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer. 2008;44:1572–6.CrossRefPubMed

48.

Onen IH, Konac E, Eroglu M, Guneri C, Biri H, Ekmekci A. No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep. 2008;35(1):17–22.CrossRefPubMed

49.

Zhai R, Liu G, Asomaning K, Su L, Kulke MH, Heist RS, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 2008;29(12):2330–4.CrossRefPubMedPubMedCentral

50.

Al-Moundhri MS, Al-Nabhani M, Burney IA, Al-Farsi AA, Al-Bahrani B. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms—a case–control study in an Omani population. Mol Carcinog. 2009;48(12):1170–6.CrossRefPubMed

51.

Maltese P, Canestrari E, Ruzzo A, Graziano F, Falcone A, Loupakis F, et al. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. Int J Colorectal Dis. 2009;24(2):165–70.CrossRefPubMed

52.

Talar-Wojnarowska R, Gasiorowska A, Olakowski M, Lekstan A, Lampe P, Smolarz B, et al. Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis. J Physiol Pharmacol. 2010;61(6):711–6.PubMed

53.

Wall SJ, Jiang Y, Muschel RJ, DeClerck YA. Meeting report: proteases, extracellular matrix, and cancer: an AACR Special Conference in Cancer Research. Cancer Res. 2003;63(15):4750–5.PubMed

54.

Murakami M, Nguyen LT, Hatanaka K, Schachterle W, Chen PY, Zhuang ZW, et al. FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest. 2011;121(7):2668–78.CrossRefPubMedPubMedCentral

55.

Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, Schonfelder G. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc Natl Acad Sci U S A. 2006;103(5):1406–11.CrossRefPubMedPubMedCentral

56.

Menendez D, Inga A, Snipe J, Krysiak O, Schonfelder G, Resnick MA. A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. Mol Cell Biol. 2007;27(7):2590–600.CrossRefPubMedPubMedCentral

57.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat. 2012;133(2):769–78.CrossRefPubMed

58.

Cancer incidence in state not so alarming, claims survey. Door-to-door study puts Punjab’s figures below the national average. In: The Tribune, Chandigarh, India. 2013. http://www.tribuneindia.com/2013/20130121/punjab.htm#3. Accessed 15 May 2014.

59.

Singletary SE, Allred C, Ashley P, Lawrence W. Bassett LW, Berry D, et al. (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20(17):3628–36

60.

Adeli K, Ogbonna G. Rapid purification of human DNA from whole blood for potential application in clinical chemistry laboratories. Clin Chem. 1990;36:261–4.PubMed

61.

Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–5.CrossRefPubMed

62.

Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27.CrossRefPubMed

63.

Salven P, Perhoniemi V, Tykka H, Maenpaa H, Joensuu H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat. 1999;53(2):161–6.CrossRefPubMed

64.

Heer K, Kumar H, Read JR, Fox JN, Monson JR, Kerin MJ. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res. 2001;7(11):3491–4.PubMed

65.

Pande D, Negi R, Khanna S, Khanna R, Khanna HD. Vascular endothelial growth factor levels in relation to oxidative damage and antioxidant status in patients with breast cancer. J Breast Cancer. 2011;14(3):181–4.CrossRefPubMedPubMedCentral

66.

Kapahi R, Manjari M, Uppal MS, Singh NR, Sambyal V, Guleria K. Association of -2549 insertion/deletion polymorphism of vascular endothelial growth factor with breast cancer in North Indian patients. Genet Test Mol Biomarkers. 2013;17(3):242–8.CrossRefPubMedPubMedCentral

67.

Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002;13(1):260–4.PubMed

68.

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003;106(4):468–71.CrossRefPubMed

69.

He Y, Ni J, Chen S, Jiang Y, Jia S, Gao Y. The vascular endothelial growth factor-2549 insertion/deletion polymorphism is not associated with susceptibility to hepatocellular carcinoma in Chinese. DNA Cell Biol. 2010;29(7):393–6.CrossRefPubMed

70.

Ungerback J, Elander N, Dimberg J, Soderkvist P. Analysis of VEGF polymorphisms, tumor expression of VEGF mRNA and colorectal cancer susceptibility in a Swedish population. Mol Med Rep. 2009;2(3):435–9.PubMed

71.

Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat. 2008;111(1):157–63.CrossRefPubMed

72.

Zhang L, Zhang G, Wang P, Gong J, Cao Y, Tang L. Association of vascular endothelial growth factor -2578C/A gene polymorphism in Chinese patients with colon cancer. Genet Test Mol Biomarkers. 2011;15(3):117–21.CrossRefPubMed

73.

Li Y, Liang J, Liu X, Liu H, Yin B, Xiao J, et al. Correlation of polymorphisms of the vascular endothelial growth factor gene and the risk of lung cancer in an ethnic Han group of North China. Exp Ther Med. 2012;3(4):673–6.PubMedPubMedCentral

74.

Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004;46(3):293–8.CrossRefPubMed

75.

Wang T, Hu K, Ren J, Zhu Q, Wu G, Peng G. Polymorphism of VEGF-2578C/A associated with the risk and aggressiveness of nasopharyngeal carcinoma in a Chinese population. Mol Biol Rep. 2010;37(1):59–65.CrossRefPubMed

76.

Hsiao PJ, Lu MY, Chiang FY, Shin SJ, Tai YD, Juo SH. Vascular endothelial growth factor gene polymorphisms in thyroid cancer. J Endocrinol. 2007;195(2):265–70.CrossRefPubMed

77.

Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006;8(2):R22.CrossRefPubMedPubMedCentral

78.

Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun. 2002;3(4):229–32.CrossRefPubMed

79.

Tzanakis N, Gazouli M, Rallis G, Giannopoulos G, Papaconstantinou I, Theodoropoulos G, et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol. 2006;94(7):624–30.CrossRefPubMed

80.

Ke Q, Liang J, Wang LN, Hu ZB, Jin GF, Zhou Y, et al. Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. Mol Carcinog. 2008;47(8):647–51.CrossRefPubMed

81.

Hofmann G, Langsenlehner U, Renner W, Langsenlehner T, Yazdani-Biuki B, Clar H, et al. Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J Cancer Res Clin Oncol. 2008;134(5):591–5.CrossRefPubMed

82.

Li Y, Wang Y, Kang S, Wang N, Zhou RM, Duan YN, et al. Association of vascular endothelial growth factor gene polymorphisms with susceptibility to epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(5):717–23.CrossRefPubMed

83.

Saenz-Lopez P, Vazquez F, Cozar JM, Carretero R, Garrido F, Ruiz-Cabello F. VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol. 2013;74(1):98–103.CrossRefPubMed

84.

Konac E, Onen HI, Metindir J, Alp E, Biri AA, Ekmekci A. Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4G/A polymorphisms and ovarian, cervical, and endometrial cancers. DNA Cell Biol. 2007;26(7):453–63.CrossRefPubMed

85.

Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B, et al. VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep. 2010;37(7):3625–30.CrossRefPubMed

86.

Szeto CC, Chow KM, Poon P, Szeto CY, Wong TY, Li PK. Genetic polymorphism of VEGF: impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int. 2004;65(5):1947–55.CrossRefPubMed

87.

Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145–7.CrossRefPubMedPubMedCentral

88.

Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park). 2005;19(4 Suppl 3):7–16.

89.

Suganthalakshmi B, Anand R, Kim R, Mahalakshmi R, Karthikprakash S, Namperumalsamy P, et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis. 2006;12:336–41.PubMed

Titel: Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians
verfasst von: Ruhi Kapahi
Kamlesh Guleria
Vasudha Sambyal
Mridu Manjari
Meena Sudan
Manjit Singh Uppal
Neeti Rajan Singh
Publikationsdatum: 01.06.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3059-1

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians

Abstract

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Autophagy and its function in radiosensitivity

Overexpression of NKX6.1 is closely associated with progressive features and predicts unfavorable prognosis in human primary hepatocellular carcinoma

Extracellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of non-small cell lung cancer patients

Interpretation of immunohistochemistry data of tumor should consider microenvironmental factors

Isothiocyanates: a class of bioactive metabolites with chemopreventive potential

Interferon gamma +874 T/A polymorphism increases the risk of cervical cancer: evidence from a meta-analysis

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Onkologie